Abstract: A pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution for administration to patients, containing a concentrate consisting of a pharmaceutically effective amount of docetaxel, a suitable solvent, which is preferably ethanol, a surfactant, which is polysorbate 80 and a pharmaceutically effective amount of an appropriate buffer; and optionally a co-solvent, consisting of an aqueous solution of a pharmaceutically effective amount of polysorbate 80 and optionally suitable organic solvent and/or a pharmaceutically effective amount of an appropriate buffer. This composition shows an excellent chemical and physical stability. The invention includes also a method of preparation of the pharmaceutical composition and the use thereof.

Abstract: A gas hydrate is produced by injecting guest molecules into voids in a layer of which temperature and pressure condition allows the guest molecules to cause to form hydrate, in a form of emulsion where liquid of the guest molecules is dispersed in water as minute particles having a size of less than a size of voids, and thereby dispersing the guest molecules uniformly into the voids in the layer.

Abstract: The invention concerns a method of production of a fine-crystalline mixture containing a non-steroid anti-inflammatory drug and an auxiliary substance, wherein a coarse-crystalline substance from the group of non-steroid anti-inflammatory drugs is dissolved in a solvent at an increased temperature, the solution is subsequently distributed at rapid chilling into a cooling liquid containing the auxiliary substance, said cooling liquid being placed in an ice bath, and the product is then filtered off and dried. It further concerns the fine-crystalline mixture of the non-steroid anti-inflammatory drug and the auxiliary substance that can be obtained by the said method. The invention further concerns a solid pharmaceutical composition, having substantially improved dissolution properties, which contains 60 to 78% w/w of the fine-crystalline mixture, 17 to 40% w/w of microcrystalline cellulose, colloidal silicon dioxide in an amount of up to 0.

Abstract: The invention concerns stable, palatable syrups for oral administration, containing S(+)-ibuprofen, hydroxypropyl beta-cyclodextrin, at least one sweetener and water, optionally essential oils. It also includes methods of preparation of the syrups of the invention, wherein crystalline S(+)-ibuprofen is dissolved in a hydroxypropyl beta-cyclodextrin aqueous solution and the final concentration of S(+)-ibuprofen is adjusted as desired by addition of an aqueous solution of sweeteners or a mixture of sweeteners and optionally of water. If the syrup of the invention contains essential oils, it is prepared by dissolving of crystalline S(+)-ibuprofen in a hydroxypropyl beta-cyclodextrin aqueous solution, combining the resulting solution with an essential oil solution in sweetener/mixture of sweeteners, preferably in a mixture of glycerin and 70% sorbitol aqueous solution, and adjusting the final concentration as desired by addition of aqueous solution of sweeteners or mixture of sweeteners and optionally of water.